Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (TDOC) received a Rule 144 notice that officer Fernando Madeira Rodrigues intends to sell 5,439 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The shares relate to restricted stock vesting on September 1, 2026, with part of the sale covering tax obligations from the equity award settlement.
The notice also lists prior sales by Rodrigues over the past three months totaling 15,249 shares of common stock for an aggregate of $114,131.29.
Teladoc Health, Inc. (TDOC) is the issuer for a planned sale of its common stock reported under Rule 144 on behalf of officer Adam Vandervoort. The notice covers up to 7,573 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with a reported aggregate market value of $47,719.74. The securities to be sold arise from a restricted stock vesting on September 1, 2026, and the filer states that the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution. Over the prior three months, Vandervoort reported selling 7,906 shares of Teladoc common stock for an aggregate value of $60,299.06.
Teladoc Health, Inc. (TDOC) is the issuer in a Form 144 notice filed for planned sales of its common stock by officer Carlos Nueno. The notice covers a planned sale of 6,200 shares of common stock through Fidelity Brokerage Services LLC on the NYSE.
The securities to be sold arise from restricted stock vesting on September 1, 2026, characterized as compensation from the issuer. A prior sale of 6,196 shares in the last three months is also disclosed. The filer notes that the sale includes shares needed to cover a tax obligation from settlement of a vested equity award.
Teladoc Health, Inc. (TDOC) is the issuer for which Charles Divita III has filed a notice of proposed sale of restricted shares under Rule 144. The notice covers the potential sale of 18,327 shares of common stock through Fidelity Brokerage Services LLC, with an approximate aggregate market value of $115,483.92 as of September 2, 2026 on the NYSE. The shares to be sold arise from restricted stock vesting on September 1, 2026 and are characterized as compensation from the issuer, with a portion of the sale intended to cover a tax obligation from the vested equity award.
Teladoc Health, Inc. (symbol: TDOC) is the issuer of record for a Form 4 filing submitted to the SEC.
Teladoc Health, Inc. (TDOC) had a Form 3 filed for Michael F. Grasher, who is identified as the company’s Chief Financial Officer. This represents his initial statement of beneficial ownership as an officer. The filing lists no reportable transactions or derivative positions and references an attached Power of Attorney.
Teladoc Health, Inc. (TDOC) appointed Michael Grasher as Chief Financial Officer, effective August 31, 2026, while Charles Divita III continues as Chief Executive Officer. Grasher brings over three decades of financial and insurance-sector experience, including CFO roles at IFG Companies, Fortegra Group and AMERISAFE, Inc., plus prior equity research experience.
His offer includes a $550,000 base salary, a one-time $500,000 sign-on bonus, an annual bonus target of 85% of base salary beginning in 2027, and a new-hire equity award with a target value of $3,000,000, split 50% restricted stock units and 50% performance stock units tied to 2026 adjusted EBITDA and 2026–2028 revenue CAGR, with multi-year vesting. An employment agreement provides salary, bonus-related amounts, health benefits and equity vesting acceleration upon certain terminations, with enhanced benefits if a qualifying termination occurs within 12 months after a change of control.
Teladoc Health, Inc. reported a planned board change. On August 10, 2026, director David B. Snow, Jr. informed the company of his intention to retire from its Board of Directors, effective September 30, 2026. He has served as a director since 2014.
The company states that Mr. Snow is retiring for personal reasons and that his decision is not due to any disagreement with the company on any matter. Teladoc expressed its appreciation for his dedicated service.
Anquillare Mark V reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. reported that director Mark V. Anquillare received a grant of 37,425 Restricted Stock Units on 2026-08-03, each representing a contingent right to one share of common stock. One-third of the units vest on the first anniversary of the grant, with the remainder vesting in eight substantially equal quarterly installments, leaving him with 37,425 RSUs directly held after the award.
Teladoc Health, Inc. identifies Mark V Anquillare as a reporting person by submitting an initial statement of beneficial ownership on Form 3 in his capacity as a director. The statement lists no equity transactions and includes a remark referencing Exhibit 24 — Power of Attorney.